What is the clinical evidence from this study?

Study design: Review. Population: Venous thromboembolism in pregnancy. Intervention: Anticoagulation (Low-molecular-weight heparins).

What question did this study set out to answer?

To review the haemostatic changes, thrombophilic conditions, and indications for prophylactic and therapeutic anticoagulation to reduce venous thromboembolism in pregnancy.

January 1, 2008The Journal of Maternal-Fetal & Neonatal Medicine

Thrombophilia and anticoagulation in pregnancy: indications, risks and management

View Full Paper

Ask AI

Bookmark

Key result

Low-molecular-weight heparins are the preferred agents for anticoagulation during pregnancy, whereas Vitamin-K antagonists are not recommended as first-line treatment due to fetal risks.

Population

Pregnant women at risk for venous thromboembolism or with thrombophilic states, including subgroups with…

Design

Review

Authors

CMCéline MontavonUniversity of Basel IHIrène HoesliUniversity of Basel WHWolfgang HolzgreveUniversity of Bonn

Discussion

Member takes

Implication

May inform anticoagulation choices in pregnancy; leaves open prospective validation for thrombophilia-specific protocols.

Key Points

To review the haemostatic changes, thrombophilic conditions, and indications for prophylactic and therapeutic anticoagulation to reduce venous thromboembolism in pregnancy.
Conducted a narrative, non-systematic review of literature published in English, German, and French over three decades, focusing primarily on publications between 2003 and 2008.
Low-molecular-weight heparins offer more clinical advantages than unfractionated heparin and are the preferred agents for anticoagulation during pregnancy.
Vitamin-K antagonists are not recommended as first-line treatment due to the risks of embryopathy and fetal hemorrhage, though they remain relevant for specialized conditions such as prosthetic heart valves.
Adverse pregnancy outcomes associated with hereditary thrombophilia provide newer indications for targeted anticoagulant administration.

Structured PICO

Population

Pregnant women at risk for venous thromboembolism (VTE) or with thrombophilic states, including subgroups with prosthetic heart valves.

Intervention

Anticoagulation therapy (low-molecular-weight heparins, unfractionated heparin, vitamin-K antagonists)

Outcome

Prevention and treatment of venous thromboembolism and adverse pregnancy outcomes

This narrative review highlights that low-molecular-weight heparins are the preferred anticoagulants during pregnancy, while vitamin-K antagonists should be avoided as first-line therapy due to fetal risks.

Cite This Study

Montavon et al. (2008) conducted a review in Venous thromboembolism in pregnancy. Anticoagulation (Low-molecular-weight heparins) was evaluated. Low-molecular-weight heparins are the preferred agents for anticoagulation during pregnancy, whereas Vitamin-K antagonists are not recommended as first-line treatment due to fetal risks.

synapsesocial.com/papers/6a918a4062841d9e29fb7df7 https://doi.org/10.1080/14767050802360791

Topics

Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Thrombophilia and anticoagulation in pregnancy: indications, risks and management

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Thrombophilia and anticoagulation in pregnancy: indications, risks and management

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider